During the corresponding time, Vistagen Therapeutics Inc recorded a revenue increase by 504.92 % year on year, sequentially revenue grew by 218.1 %. While revenue at the Vistagen Therapeutics Inc 's corporate clients
Vistagen Therapeutics Inc's Comment on Sales, Marketing and Customers
The company complies with healthcare laws governing customer incentive programs, patient assistance programs, and business arrangements involving pharmaceutical manufacturers and various healthcare stakeholders. The federal Anti-Kickback Statute prohibits offering or receiving remuneration to induce the purchase or recommendation of items reimbursable under federal healthcare programs such as Medicare and Medicaid. This statute applies to relationships between pharmaceutical manufacturers and prescribers, purchasers, formulary managers, and beneficiaries. Additionally, the Federal Civil False Claims Act prohibits submitting false claims or records to the federal government and has been used to address liability related to kickbacks, improper referrals, inaccurate government pricing metrics, off-label promotion, and misrepresentations about products or services. The company’s compliance efforts encompass interactions with prescribers, purchasers, formulary managers, beneficiaries, and federal healthcare programs including Medicare and Medicaid.
: Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, continues to advance its neuroscience initiatives. With a focus on using nose-to-brain neurocircuitry, the company is developing intranasal product candidates known as pherines, targeting neurological and psychiatric conditions. Vistagen will disclose its fiscal year 2026 second-quarter financial results on November 13, 2025. Additionally, the company has presented new findings on Social Anxiety Disorder (SAD) and received a U.S. patent for AV-101 to tackle neuropathic pain, showcasing its commitment to addressing unmet needs in mental health and pain management. Vistagen s Financial Reporting and Conference Call: Located in Sout...
Vistagen Expands Global Intellectual Property Portfolio with New Patents for Migraine Treatment and Reports Positive Results for PH15 StudyVistagen, a clinical-stage neuroscience-focused biopharmaceutical company, has recently broadened its global intellectual property portfolio by obtaining new patents related to the use of PH80 in treating migraines. PH80 is a non-systemic hormone-based therapy aimed at targeting psychiatric and neurological disorders through nose-to-brain neurocircuitry. Additionally, the company has reported its fiscal year 2024 financial results and provided a corporate update, showcasing remarkable accomplishments. Lastly, Vistagen announced positive results from a Phase 2A pilot stud...
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueVistagen, a leading biopharmaceutical company specializing in neuroscience therapies for psychiatric and neurological disorders, has recently released positive results from a Phase 2A pilot study of their investigational pherine nasal spray, PH15. The study focused on evaluating the efficacy of PH15 in improving psychomotor impairment caused by mental fatigue. The findings have shown remarkable potential for PH15 in enhancing reaction time compared to a placebo.Mental fatigue is a prevalent issue affecting individuals across the globe. It can arise from prolonged periods of ...
Vistagen Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company complies with healthcare laws governing customer incentive programs, patient assistance programs, and business arrangements involving pharmaceutical manufacturers and various healthcare stakeholders. The federal Anti-Kickback Statute prohibits offering or receiving remuneration to induce the purchase or recommendation of items reimbursable under federal healthcare programs such as Medicare and Medicaid. This statute applies to relationships between pharmaceutical manufacturers and prescribers, purchasers, formulary managers, and beneficiaries. Additionally, the Federal Civil False Claims Act prohibits submitting false claims or records to the federal government and has been used to address liability related to kickbacks, improper referrals, inaccurate government pricing metrics, off-label promotion, and misrepresentations about products or services. The company’s compliance efforts encompass interactions with prescribers, purchasers, formulary managers, beneficiaries, and federal healthcare programs including Medicare and Medicaid.
Sources:
Vistagen Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vistagen Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vistagen Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
13.55 %